Davenport A, Roberts N B
Renal Unit, Royal Liverpool Hospital, UK.
Nephron. 1989;52(3):253-8. doi: 10.1159/000185652.
Serum aluminium was monitored in 19 patients admitted with acute oligo-anuric renal failure. The maximum serum aluminium obtained during the course of treatment was greater (p less than 0.05) in 4 patients treated by haemodialysis alone, mean +/- sem 3.78 +/- 0.71 mumol/l than in 4 patients treated only by haemofiltration, 0.60 +/- 0.22 greater (p less than 0.05) during treatment with haemodialysis, 2.7 +/- 0.62 mumol/l than during treatment with haemofiltration, 1.36 +/- 0.15 mumol/l. There was a significant positive correlation between the maximum serum aluminium during treatment with haemodialysis and the number of hours of haemodialysis given (r = 0.76, p less than 0.001). There was no significant increase in serum aluminium due to the administration of human albumin solutions. The aluminium content of dialysate water represents a major source of aluminium in patients with acute renal failure; prevention by reverse-osmosis water purification is recommended.
对19例急性少尿性肾衰竭患者的血清铝水平进行了监测。单纯接受血液透析治疗的4例患者,治疗期间血清铝的最高值更高(p<0.05),平均±标准误为3.78±0.71μmol/L,高于仅接受血液滤过治疗的4例患者;血液透析治疗期间血清铝的最高值为2.7±0.62μmol/L,高于血液滤过治疗期间的1.36±0.15μmol/L,差值为0.60±0.22,差异有统计学意义(p<0.05)。血液透析治疗期间血清铝的最高值与血液透析时长之间存在显著正相关(r=0.76,p<0.001)。输注人白蛋白溶液未导致血清铝显著升高。透析用水中的铝含量是急性肾衰竭患者铝的主要来源;建议采用反渗透水净化进行预防。